 | Up a level |
Jump to: 2018
Number of items: 1.
2018
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041